Cardiol Therapeutics Inc. (CRDL) Stock Price & Analysis
Cardiol Therapeutics Inc. (CRDL) — MoonshotScore 49/100 (Fair band), calculated Nov 18, 2026. Price $0.8626 (-2.28%), as of the Nov 20, 2026 trading session; market cap $110M.
Educational signal · not a buy or sell recommendation · How to read this
Cardiol Therapeutics Inc. · CRDL · NASDAQ
Cardiol Therapeutics Inc. is a clinical-stage life sciences company focused on developing therapies for cardiovascular disease.
Price as of Nov 20, 2026
Key Statistics
MoonshotScore v2 · Cardiol Therapeutics (CRDL)
FairWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
A strong balance sheet, but weak quality, weak growth and an expensive valuation. Business Quality: Thin; Financial Safety: Sound; Valuation: Rich; Growth Durability: Fading; Momentum: Slipping.
- EPS beat 0 of the last 4 reports
- Altman Z 5.98 · Piotroski F 2
Holding back: weak fundamentals
Helping: balance-sheet strength
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 51 | Fair | |
| 51 | Fair | |
| 51 | Fair | |
| 49 | Fair | |
| 49 | Fair | |
| 49 | Fair |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $0.8626 | |
| Change on the day | -2.28% | |
| Market capitalisation | $110M | — |
| Shares traded on the day | 553.0K |
Price & events
Other perspectives
Council score for Cardiol Therapeutics (CRDL): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
5-Factor Breakdown
Legends Council
6 lenses, 6 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 21, 2026
Munger's Mindset
Balance Sheet & Valuation
Read on: Nov 20, 2026
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
The Munger lens reads the current price as fairly valued against its own estimate of value.
Readings on this page are from Nov 21, 2026, except a card that shows its own read date.
What is Cardiol Therapeutics (CRDL), and what does it report?
Short answer
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Cardiol Therapeutics Inc. (CRDL) is listed on NASDAQ. It employs 18 people. The market values it at $110M.
What do the latest results show for Cardiol Therapeutics (CRDL)?
Short answer · as of
Against analyst estimates the company has EPS beat 0 of the last 4 reports.
What are the financial strengths and risks for Cardiol Therapeutics (CRDL)?
Short answer
The MoonshotScore pillars rate balance-sheet strength as strengths. What is holding it back is weak fundamentals. The distress and quality screens read Altman Z 5.98 · Piotroski F 2. Trailing ratios: ROA -96.8% · current ratio 6.26.
Data-derived red flags
- Listing risk — at $0.8626 the shares sit below the $1.00 minimum bid NASDAQ requires for continued listing.
- Inconsistent delivery — missed Wall Street EPS estimates in 0 of the last 4 reported quarters.
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
What should you watch next at Cardiol Therapeutics (CRDL)?
Short answer · as of
Analyst estimates on file carry FY2026 revenue $1.13M · EPS -0.43 · 5 analysts.
What the records here don't tell us
- The next earnings date is not yet scheduled in the calendar we read.
- No insider Form 4 transaction falls inside the window this page reads.
- No quarterly income statement is held for CRDL.
Checked against the records this page reads, on the dates shown above.
How does Cardiol Therapeutics compare with its peers?
Short answer
Cardiol Therapeutics's score ranks 3rd of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
| Company | Price | Market value | Score |
|---|---|---|---|
| $6.02 Nov 20, 2026 | $341M | 71 5-pillar Nov 18, 2026 | |
| $5.84 Nov 20, 2026 | $87.6M | 51 5-pillar Nov 18, 2026 | |
| Cardiol Therapeutics (CRDL) — this page | $0.8626 | $110M | 49 |
| $2.40 Nov 20, 2026 | $172M | 38 5-pillar Nov 18, 2026 | |
| $0.58 Nov 20, 2026 | $82.3M | 35 5-pillar Nov 18, 2026 | |
| $1.52 Nov 19, 2026 | $72.0M | 32 5-pillar Nov 18, 2026 | |
| $1.17 Nov 20, 2026 | $285M | 32 5-pillar Nov 18, 2026 | |
| $3.30 Nov 20, 2026 | $93.2M | 31 5-pillar Nov 18, 2026 | |
| $0.79 Nov 20, 2026 | $40.8M | 31 5-pillar Nov 18, 2026 | |
| $3.24 Nov 20, 2026 | $42.0M | 30 5-pillar Nov 18, 2026 | |
| $0.77 Nov 20, 2026 | $100M | 28 5-pillar Nov 18, 2026 | |
| $5.05 Nov 20, 2026 | $260M | 24 5-pillar Nov 18, 2026 | |
| $6.39 Nov 20, 2026 | $242M | 21 5-pillar Nov 18, 2026 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Revenue estimate
- $1.13M
- EPS estimate
- $-0.43
Measured against a quoted price of $0.8626 (as of Nov 20, 2026).
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held CRDL in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported CRDL in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about Cardiol Therapeutics (CRDL)?
Cardiol Therapeutics Stock: Key Questions Answered
These answers are editorial: 1 of these 9 answers is drawn from the CRDL research dossier (written May 5, 2026 by gemini-2.0-flash); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.
What does the MoonshotScore mean for CRDL?
CRDL carries the MoonshotScore stated above — the Fair band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers.
Is CRDL a good stock to buy?
Stock Expert AI does not rate CRDL buy, sell or hold. Cardiol Therapeutics Inc. carries a MoonshotScore, in the Fair band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the CRDL stock price today?
The last price recorded for Cardiol Therapeutics Inc. (CRDL), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What do analysts say about CRDL stock?
Analyst coverage of Cardiol Therapeutics Inc. (CRDL) is not available within the provided context. Therefore, a summary of analyst consensus, key valuation metrics, and growth considerations cannot be provided. Further research on analyst ratings and reports would be needed to assess market sentiment and expectations for CRDL stock.
What are the key factors to evaluate for CRDL?
Cardiol Therapeutics Inc. (CRDL) holds a MoonshotScore in the low range. These partnerships could provide access to funding, expertise, and distribution networks, enhancing Cardiol's growth prospects. Not financial advice.
How frequently does CRDL data refresh on this page?
CRDL's price is the last quote we recorded, from the Nov 20, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven CRDL's recent stock price performance?
Cardiol Therapeutics Inc. (CRDL) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Lead product (CardiolRx) in Phase II/III trials. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider CRDL overvalued or undervalued right now?
Cardiol Therapeutics Inc. (CRDL) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Can I buy fractional shares of CRDL?
Fractional-share availability for Cardiol Therapeutics Inc. (CRDL) depends on your brokerage, account and supported securities. Check the broker's current eligibility, minimums and fees before placing an order.
Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated May 5, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 13 figures on this page — 6 from Financial Modeling Prep (FMP), 6 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com